Novel Cardiovascular Diagnostic Device with 
Significant Potential to Reduce Hospitalization 
for Heart Failure Patients

The Next Generation of Pulmonary Artery Catheters

HemoCath is a novel cardiovascular monitoring & diagnostic device that has significant potential to improve outcomes and reduce hospitalization for patients with congestive heart failure (CHF).

HemoCath provides the most important measures of cardiac function and fluid status. It allows more frequent/accurate adjustments of medication dosing for heart failure patients – so patients more rapidly reach their optimal fluid level – leading to better patient outcomes and sooner hospital discharge. HemoCath (4F) is easily inserted into a vein on the upper arm.

Intelligent Hemodynamic Monitoring Platform

Heart failure (HF) is a global pandemic affecting at least 26 million people worldwide  —  ​5.7 million people in the US  —  and projections in the near future are worrisome. HF health expenditures are considerable and will increase dramatically with an ageing population.

HemoCloud is an intelligent hemodynamic monitoring platform that closely monitors a patient's heart and notifies healthcare professionals when a patient's condition is worsening.